Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Oncobiologics, Inc. (OTLK : NSDQ)
 
 • Company Description   
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.

Number of Employees: 9

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.57 Daily Weekly Monthly
20 Day Moving Average: 696,273 shares
Shares Outstanding: 225.94 (millions)
Market Capitalization: $354.73 (millions)
Beta: 0.82
52 Week High: $3.27
52 Week Low: $1.19
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.77% 1.62%
12 Week -4.27% 5.24%
Year To Date 15.44% 36.56%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
485 ROUTE 1 SOUTH BUILDING F SUITE 320
-
ISELIN,NJ 08830
USA
ph: 609-619-3990
fax: -
jeremy@lifesciadvisors.com http://www.outlooktherapeutics.com
 
 • General Corporate Information   
Officers
C. Russell Trenary - Chief Executive Officer; President and Director
Lawrence A. Kenyon - Chief Financial Officer;Treasurer; Secretary and D
Ralph H. Thurman - Executive Chairman
Yezan Haddadin - Director
Kurt J. Hilzinger - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 69012T206
SIC: 2836
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
Share - Related Items
Shares Outstanding: 225.94
Most Recent Split Date: 3.00 (0.13:1)
Beta: 0.82
Market Capitalization: $354.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 9.86
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -12.50%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -234.06
12/31/21 - -244.94
09/30/21 - -772.40
ROA
03/31/22 - -118.32
12/31/21 - -118.50
09/30/21 - -187.65
Current Ratio
03/31/22 - 2.12
12/31/21 - 3.88
09/30/21 - 3.19
Quick Ratio
03/31/22 - -
12/31/21 - 3.88
09/30/21 - 3.19
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.16
12/31/21 - 0.22
09/30/21 - 0.03
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.20
09/30/21 - 2.37
Debt-to-Capital
03/31/22 - 0.03
12/31/21 - 16.46
09/30/21 - 70.29
 

Powered by Zacks Investment Research ©